Knowledge

Category:Experimental anti-obesity drugs

Source 📝

56: 116: 76: 32: 302: 137: 367: 362: 96: 150: 213: 230: 356: 343: 290: 331: 319: 278: 242: 208: 120: 100: 80: 36: 196: 184: 179: 167: 60: 218: 314: 162: 254: 20:
This category has the following 5 subcategories, out of 5 total.
136:
The following 20 pages are in this category, out of 20 total.
266: 133:
Pages in category "Experimental anti-obesity drugs"
8: 138:This list may not reflect recent changes 7: 142: 53: 22: 14: 57:Cannabinoid receptor antagonists 303:Prohibitin-targeting peptide 1 1: 384: 117:Neuropeptide Y antagonists 77:Glucagon receptor agonists 33:Amylin receptor agonists 151:5-HT2C receptor agonist 368:Experimental drugs 363:Anti-obesity drugs 214:Denatonium acetate 97:METAP2 inhibitors 375: 231:Etiocholanedione 122: 102: 82: 62: 55: 38: 383: 382: 378: 377: 376: 374: 373: 372: 353: 352: 351: 350: 349: 348: 336: 324: 307: 295: 283: 271: 259: 247: 235: 223: 201: 189: 172: 155: 130: 129: 128: 127: 124: 123: 107: 104: 103: 87: 84: 83: 67: 64: 63: 52: 43: 40: 39: 12: 11: 5: 381: 379: 371: 370: 365: 355: 354: 347: 346: 340: 337: 335: 334: 328: 325: 323: 322: 317: 311: 308: 306: 305: 299: 296: 294: 293: 287: 284: 282: 281: 275: 272: 270: 269: 263: 260: 258: 257: 251: 248: 246: 245: 239: 236: 234: 233: 227: 224: 222: 221: 216: 211: 205: 202: 200: 199: 193: 190: 188: 187: 182: 176: 173: 171: 170: 165: 159: 156: 154: 153: 147: 144: 143: 134: 131: 126: 125: 115: 114: 111: 108: 106: 105: 95: 94: 91: 88: 86: 85: 75: 74: 71: 68: 66: 65: 51: 50: 47: 44: 42: 41: 31: 30: 27: 24: 23: 18: 15: 13: 10: 9: 6: 4: 3: 2: 380: 369: 366: 364: 361: 360: 358: 345: 344:Vutiglabridin 342: 341: 338: 333: 330: 329: 326: 321: 318: 316: 313: 312: 309: 304: 301: 300: 297: 292: 289: 288: 285: 280: 277: 276: 273: 268: 265: 264: 261: 256: 253: 252: 249: 244: 241: 240: 237: 232: 229: 228: 225: 220: 217: 215: 212: 210: 207: 206: 203: 198: 195: 194: 191: 186: 183: 181: 178: 177: 174: 169: 166: 164: 161: 160: 157: 152: 149: 148: 145: 141: 139: 132: 118: 113: 112: 109: 98: 93: 92: 89: 78: 73: 72: 69: 58: 54: 49: 48: 45: 34: 29: 28: 25: 21: 17:Subcategories 16: 291:Orforglipron 135: 19: 332:Tesofensine 320:Survodutide 279:Monlunabant 243:Fluasterone 209:Dapiglutide 357:Categories 197:Cetilistat 185:Bimagrumab 180:Benfluorex 168:Azalanstat 61:(1 C, 1 P) 219:Diazoxide 315:S-309309 163:AdipoRon 255:GLY-200 121:(5 P) 101:(3 P) 81:(9 P) 37:(8 P) 267:HU6 146:0–9 359:: 140:. 119:‎ 99:‎ 79:‎ 59:‎ 35:‎ 339:V 327:T 310:S 298:P 286:O 274:M 262:H 250:G 238:F 226:E 204:D 192:C 175:B 158:A 110:N 90:M 70:G 46:C 26:A

Index

Amylin receptor agonists

Cannabinoid receptor antagonists
Glucagon receptor agonists
METAP2 inhibitors
Neuropeptide Y antagonists
This list may not reflect recent changes
5-HT2C receptor agonist
AdipoRon
Azalanstat
Benfluorex
Bimagrumab
Cetilistat
Dapiglutide
Denatonium acetate
Diazoxide
Etiocholanedione
Fluasterone
GLY-200
HU6
Monlunabant
Orforglipron
Prohibitin-targeting peptide 1
S-309309
Survodutide
Tesofensine
Vutiglabridin
Categories
Anti-obesity drugs
Experimental drugs

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.